Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
Journal of Clinical Oncology2008Vol. 27(4), pp. 526–534
Citations Over TimeTop 10% of 2008 papers
José Baselga, Milvia Zambetti, Antonio Llombart‐Cussac, Georgy Manikhas, E. Kubista, Günther Steger, А. Н. Махсон, Sergei Tjulandin, H Ludwig, Mark Verrill, Eva Ciruelos, Suzanne Egyházi, Lian Xu, Kim E. Zerba, Hye-Rim Lee, Edwin Clark, Susan Galbraith
Abstract
indicate an inverse relation between ER expression levels and ixabepilone sensitivity. Neoadjuvant ixabepilone demonstrated promising activity and a manageable safety profile in patients with invasive breast tumors.
Related Papers
- → Ixabepilone: Clinical Role in Metastatic Breast Cancer(2011)20 cited
- → Novel Combinations for the Treatment of Metastatic Breast Cancer(2010)9 cited
- → Identifying Subsets of Metastatic Breast Cancer Patients Likely to Benefit From Treatment With the Epothilone B Analog Ixabepilone(2010)2 cited
- → Balancing the efficacy and safety of ixabepilone: optimizing treatment in metastatic breast cancer(2012)
- ASCO: Paclitaxel Proves Better Than Newer Chemotherapies in Metastatic Breast Cancer(2012)